It has been disclosed that the National Health Insurance Scheme (NHIS) now covers the treatment of four (4) types of child cancers in Ghana.
This was revealed by the Mayor of Tamale, Sule Salifu when he was speaking on behalf of the Northern Regional Minister at event to open the New Cancer Centre at Tamale Teaching Hospital on Wednesday December 8.
“The National Health Insurance Scheme has absorbed the cost of treating four child cancers including throat cancer, eye cancer, brain tumor and wind cancer. The rendering of oncoiogy services in Tamale will make treatment easily accessible to the people of Tamale and its environs”, the Northern Regional Minister’s rep said.
Announcing the launch of the new Tamale Teaching Hospital in partnership with the government of Ghana to expand access to oncology services by Philip Anderson, General Manager for Roche Ghana, Dr Kareem Mumuni, he said the Tamale Teaching Hospital (TTH) is the third new centre launched this year as part of an agreement Roche signed with the Ministry of Health in June to develop infrastructure to deliver cancer care.
By expanding oncology services at three new cancer treatment centres, Roche and the Ghana Ministry of Health are advancing their goal of alleviating geographic access barriers to quality cancer care; supporting capacity development and training for health care providers; and supporting awareness creation in communities.
“It’s an honor to open the third cancer centre in Ghana at the Tamale Teaching Hospital. Combined with the centres at the Cape Coast and Ho Teaching Hospitals, I am incredibly hopeful about the positive impact we will see for cancer care in the country and our ability to deliver innovation to patients in the region,” Philip Anderson, General Manager for Roche Ghana told the gathering.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.